PaySign’s first-quarter 2026 earnings call revealed a significant inflection point for the company, marked by robust revenue growth, improved profitability, and strategic positioning within healthcare and plasma sectors. The company reported a 50.8% increase in revenue to $28 million, surpassing guidance, alongside a 110% rise in net income to $5.4 million and a 113% increase in adjusted EBITDA to $10.6 million. These figures highlight strong operational leverage, with operating margins expanding by over 10 percentage points year-over-year.
The patient affordability business emerged as the primary growth driver, with revenue soaring 82% year-over-year to $15.7 million. This segment’s growth was fueled by a combination of new program launches, organic expansion of existing programs, and increased engagement with major pharmaceutical clients. PaySign launched four new programs in Q1, bringing the total to 135 active programs, and aims to exceed the 55 net program additions achieved in 2025. The segment also delivered over $540 million in financial assistance to patients, underscoring its expanding role in supporting access to high-cost branded therapies.
PaySign’s Dynamic Business Rules Technology continues to provide differentiated value by helping pharmaceutical manufacturers manage complex copay, maximizer, and accumulator programs. The company’s participation at the Asembia Specialty Pharmacy Summit in April further reinforced its strong industry relationships and pipeline, with more than 50 meetings and new business secured during the event.
In the plasma donor compensation business, revenue increased 25% to $11.7 million despite strategic closures of underperforming plasma centers. The company exited Q1 with 573 centers, slightly fewer than at the end of 2025, but expects closures to have minimal impact as donors typically shift to nearby centers. Advances in plasmapheresis hardware have unlocked excess capacity, enabling revenue growth without proportional center expansion. PaySign is also pursuing international opportunities, notably in Europe and Asia, for its SaaS solutions, supported by recent engagements at the International Plasma Protein Congress in Milan.
Looking ahead, PaySign anticipates full-year revenue growth of 30-35%, driven by continued scaling of its patient affordability platform, expansion of SaaS offerings, and new partnerships in pharmaceutical and plasma collection industries. While the company’s outlook appears positive, it remains subject to typical industry risks and operational challenges, including payer and pharmacy plan transitions and market dynamics.
In summary, PaySign’s Q1 2026 performance demonstrates strong momentum and validates its strategic focus on scalable platforms within healthcare affordability and plasma collection. The company’s ability to leverage technology and deepen industry relationships positions it well for sustained growth and value creation, though ongoing monitoring of execution risks and market conditions is warranted.